Skip to main content

PDS Biotechnology Corp

PDSB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001472091

No open-market purchases or sales by PDS Biotechnology Corp insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $6.78M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding PDS Biotechnology Corp changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of PDSB: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders6653−13
Shares5.97M5.93M−43.2K (−0.7%)
Value$48.3M$36.7M−$11.6M (−24.1%)

New holders (7)

Institutions that held PDS Biotechnology Corp at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to PDSB in Q1 2022
InstitutionSharesValue% of portfolio
Knightsbridge Asset Management, LLC21,992$136.0K0.05%
Gsa Capital Partners LLP14,321$89.0K0.01%
Andesa Financial Management Inc.12,500$77.0K0.04%
Minot Wealth Management LLC10,000$62.0K0.01%
UBS Group AG2,499$15.0K0.00%
Quantbot Technologies LP700$4.00K0.00%
Captrust Financial Advisors250$2.00K0.00%

Sold out (20)

Institutions that held PDS Biotechnology Corp at the end of Q4 2021 and filed for Q1 2022 without it.